Introduction: A number of neurological complications of COVID-19 have been identified, including cranial nerve paralyses. We present a series of 10 patients with lower cranial nerve involvement after severe COVID-19 infection requiring hospitalization in an intensive care unit. Methods: We conducted a retrospective, observational study of patients admitted to the post-intensive care unit (p-ICU) of Besançon University Hospital (France) between March 16 and May 22, 2020. We included patients with confirmed COVID-19 and cranial neuropathy at admission to the p-ICU. All these patients were treated by orotracheal intubation, and all but one underwent prone-position ventilation therapy. Results: Of the 88 patients admitted to the p-ICU, 10 patients (11%) presented at least 1 cranial nerve palsy. Of these 10 patients, 9 had a hypoglossal nerve palsy and 8 of these also had a deficit in another cranial nerve. The most frequent association was between hypoglossal and vagal palsies (5 patients). None of the patients developed neurological signs related to a global neuropathy. We found no correlation between the intensity of the motor limb weakness and the occurrence of lower cranial nerve palsies. All but 2 of the patients recovered within less than a month. Conclusion: The mechanical compressive hypothesis, linked to the prone-position ventilation therapy, appears to be the major factor. The direct toxicity of SARS-CoV-2 and the context of immune dysfunction induced by the virus may be involved in a multifactorial etiology.

1.
Dinkin
M
,
Gao
V
,
Kahan
J
,
Bobker
S
,
Simonetto
M
,
Wechsler
P
,
Author response: COVID-19 presenting with ophthalmoparesis from cranial nerve palsy
.
Neurology
.
2020
;
95
(
5
):
411
3
. .
2.
Decavel
P
,
Petit
C
,
Tatu
L
.
Tapia syndrome at the time of the COVID-19 pandemic: lower cranial neuropathy following prolonged intubation
.
Neurology
.
2020
;
95
(
7
):
312
3
. .
3.
Gutiérrez-Ortiz
C
,
Méndez-Guerrero
A
,
Rodrigo-Rey
S
,
San Pedro-Murillo
E
,
Bermejo-Guerrero
L
,
Gordo-Mañas
R
,
Miller Fisher syndrome and polyneuritis cranialis in COVID-19
.
Neurology
.
2020
;
95
(
5
):
e601
5
. .
4.
Li
YC
,
Bai
WZ
,
Hashikawa
T
.
The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients
.
J Med Virol
.
2020
;
92
(
6
):
552
5
. .
5.
Costello
F
,
Dalakas
MC
.
Cranial neuropathies and COVID-19: neurotropism and autoimmunity
.
Neurology
.
2020
;
95
(
5
):
195
6
. .
6.
Stevens
RD
,
Marshall
SA
,
Cornblath
DR
,
Hoke
A
,
Needham
DM
,
de Jonghe
B
,
A framework for diagnosing and classifying intensive care unit-acquired weakness
.
Crit Care Med
.
2009
;
37
(
10 Suppl
):
S299
308
. .
7.
Shah
AC
,
Barnes
C
,
Spiekerman
CF
,
Bollag
LA
.
Hypoglossal nerve palsy after airway management for general anesthesia: an analysis of 69 patients
.
Anesth Analg
.
2015
;
120
(
1
):
105
20
. .
8.
Urbanová
P
,
Hejna
P
,
Zátopková
L
,
Šafr
M
.
The morphology of human hyoid bone in relation to sex, age and body proportions
.
Homo
.
2013
;
64
(
3
):
190
204
. .
9.
Tatu
L
,
Nono
S
,
Grácio
S
,
Koçer
S
.
Guillain-Barré syndrome in the COVID-19 era: another occasional cluster?
J Neurol
.
2021
;
268
(
4
):
1198
200
.
10.
Gigli
GL
,
Bax
F
,
Marini
A
,
Pellitteri
G
,
Scalise
A
,
Surcinelli
A
,
Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster?
J Neurol
.
2021
;
268
(
4
):
1195
7
.
11.
Boğa
I
,
Aktas
S
.
Treatment, classification, and review of Tapia syndrome
.
J Craniofac Surg
.
2010
;
21
(
1
):
278
80
. .
12.
De Luca
P
,
Cavaliere
M
,
Scarpa
A
,
Savignano
L
,
Cassandro
E
,
Cassandro
C
,
Rehabilitation protocol for unilateral laryngeal and lingual paralysis (Tapia syndrome)
.
Ear Nose Throat J
.
2021
;
100
:
734S
7S
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.